Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05236751 · ClinicalTrials.gov registry record
Hyperglycemia in Neurosurgery
A clinical trial, sponsored by Boston Medical Center.
- Completed
- Registry status
- 52
- Enrollment target
NCT05236751 is a clinical trial that has completed, run by Boston Medical Center. The registered enrollment target is 52 participants.
The verdict
NCT05236751 has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Poor glycemic control is recognized as a risk factor for postoperative infection. For the neurosurgical patient, postoperative infection can lead to devastating complications such as meningitis, encephalitis and death. Neurosurgical patients often receive high doses of medications that increase blood glucose levels such as steroids, placing them at a potentially higher risk for postoperative infection. The purpose of this multisite observational study is to assess the impact of severe intraoperative hyperglycemia as a risk factor for postoperative infection in the neurosurgical patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2023-05-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05236751
The ClinicalTrials.gov registry entry for NCT05236751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05236751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05236751 about?
NCT05236751 is a clinical study titled "Hyperglycemia in Neurosurgery". Poor glycemic control is recognized as a risk factor for postoperative infection. For the neurosurgical patient, postoperative infection can lead to devastating complications such as meningitis, encephalitis and death. Neurosurgical patients often receive high doses of medications that increase bloo...
What is the current status of trial NCT05236751?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2021-05-24. Estimated completion is 2023-05-13.
Who is sponsoring clinical trial NCT05236751?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.